Cancer BiologybioRxivPreprint
TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia
Jeevitha D’Souza, Camille J. Leung, Aishwarya C. Ballapuram…·Benjamin J. Huang
This study shows TP53 mutations cause resistance to revumenib in AML and suggests combining MCL-1 inhibitors with menin inhibitors could be effective.
3 citations